Tito Fojo

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Why RECIST works and why it should stay--counterpoint
    Antonio T Fojo
    NCI, NIH, Medicine Branch, Bethesda, MD 20892, USA
    Cancer Res 72:5151-7; discussion 5158. 2012
  2. doi request reprint Mechanisms of resistance to PARP inhibitors--three and counting
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Discov 3:20-3. 2013
  3. doi request reprint Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, Bethesda, Maryland, USA
    Clin Cancer Res 16:5972-80. 2010
  4. pmc Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institiutes of Health, Bldg 10, Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20892
    J Natl Cancer Inst 103:1738-40. 2011
  5. ncbi request reprint Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
    Robert W Robey
    Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 12:1547-55. 2006
  6. pmc A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors
    Ronan J Kelly
    Medical Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA
    Oncologist 17:512. 2012
  7. ncbi request reprint The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53
    Masaki Kitazono
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 1:665-8. 2002
  8. ncbi request reprint The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems
    Merrill E Goldsmith
    Experimental Therapeutics Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room 13N240, MSC 1903, Bethesda, MD 20892, USA
    Mol Cancer Ther 6:496-505. 2007
  9. ncbi request reprint Evidence for microtubule target engagement in tumors of patients receiving ixabepilone
    Sen H Zhuang
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 13:7480-6. 2007
  10. pmc Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    Susan E Bates
    Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 148:256-67. 2010

Detail Information

Publications78

  1. doi request reprint Why RECIST works and why it should stay--counterpoint
    Antonio T Fojo
    NCI, NIH, Medicine Branch, Bethesda, MD 20892, USA
    Cancer Res 72:5151-7; discussion 5158. 2012
    ..S. Food and Drug Administration (FDA) approvals in solid tumors to support our position that current RECIST thresholds should be retained...
  2. doi request reprint Mechanisms of resistance to PARP inhibitors--three and counting
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Discov 3:20-3. 2013
    ..Models that help us understand how this happens are a first step to better and more effective chemotherapeutics...
  3. doi request reprint Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, Bethesda, Maryland, USA
    Clin Cancer Res 16:5972-80. 2010
    ....
  4. pmc Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institiutes of Health, Bldg 10, Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20892
    J Natl Cancer Inst 103:1738-40. 2011
    ....
  5. ncbi request reprint Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
    Robert W Robey
    Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 12:1547-55. 2006
    ..These studies suggest that depsipeptide induces its own mechanism of resistance and thus provide a basis for clinical trials evaluating depsipeptide in combination with a Pgp inhibitor...
  6. pmc A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors
    Ronan J Kelly
    Medical Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA
    Oncologist 17:512. 2012
    ..Laboratory studies showed potent and durable inhibition of Pgp, and in phase I studies CBT-1® did not alter the pharmacokinetics of paclitaxel or doxorubicin...
  7. ncbi request reprint The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53
    Masaki Kitazono
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 1:665-8. 2002
    ..This study validates the concept of pseudo-null p53, as a mechanism of p53 inactivation, and demonstrates that pseudo-null p53 can be rescued pharmacologically...
  8. ncbi request reprint The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems
    Merrill E Goldsmith
    Experimental Therapeutics Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room 13N240, MSC 1903, Bethesda, MD 20892, USA
    Mol Cancer Ther 6:496-505. 2007
    ..These studies suggest that FK228 treatment prior to adenovirus infection could increase the efficiency of adenovirus gene therapy in xenograft model systems...
  9. ncbi request reprint Evidence for microtubule target engagement in tumors of patients receiving ixabepilone
    Sen H Zhuang
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 13:7480-6. 2007
    ..Our objective was to develop a straightforward and dependable assay to show tubulin target engagement in tumor tissue after treatment of patients with ixabepilone(BMS-247550; Ixempra)...
  10. pmc Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    Susan E Bates
    Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 148:256-67. 2010
    ....
  11. ncbi request reprint The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells
    Merrill E Goldsmith
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:5394-401. 2003
    ..The purpose of these studies was to analyze the effects of FK228 on cultured normal human cells before initiating animal studies...
  12. pmc Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))
    Robert W Robey
    Medical Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Biochem Pharmacol 75:1302-12. 2008
    ..CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed. Further clinical studies with CBT-1 are warranted...
  13. ncbi request reprint A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
    Sen H Zhuang
    Cancer Therapeutics Branch, Center of Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 103:1932-8. 2005
    ..The authors conducted a Phase I study by administering ixabepilone to patients as a 1-hour intravenous infusion daily for 3 consecutive days every 21 days...
  14. doi request reprint A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma
    Hui Huang
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 16:1634-41. 2010
    ..This phase II study was conducted to assess the efficacy and safety of ixabepilone in patients with metastatic renal cell carcinoma...
  15. pmc The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer
    Ciara O'Sullivan
    Medical Oncology Branch C O, M E, M V, J W, S B, T F, Center for Cancer Research, Laboratory of Pathology S P, and National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis S X Y, D N, National Cancer Institute, and Radiology and Imaging Sciences A M V, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Endocrinol Metab 99:1291-7. 2014
    ..Published evidence indicates many ACCs express the vascular endothelial growth factor receptor (VEGFR), suggesting inhibiting vascular endothelial growth factor signaling could potentially impact tumor growth...
  16. pmc Operative management for recurrent and metastatic adrenocortical carcinoma
    Nicole M Datrice
    Surgery Branch, National Cancer Institute NIH, Building 10 Hatfield CRC Room 4 3961, 10 Center Drive, Bethesda, MD 20892, USA
    J Surg Oncol 105:709-13. 2012
    ..A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease...
  17. pmc Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells
    Lyn M Huff
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute and Laboratory of Integrative and Medical Biophysics, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland 20892, USA
    Cancer Res 70:5870-9. 2010
    ..These results underscore the fine control that occurs in neural cells and may further our understanding of neurotoxicity following MDAs...
  18. pmc A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:569-80. 2011
    ..Here we report the results of a pharmacokinetic and pharmacodynamic trial using a third-generation, potent, noncompetitive inhibitor of Pgp, tariquidar (XR9576), in combination with docetaxel...
  19. ncbi request reprint Characterization of gene rearrangements leading to activation of MDR-1
    Lyn M Huff
    Medical Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 281:36501-9. 2006
    ....
  20. pmc Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage
    Wilfred D Stein
    Medical Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 13:1055-62. 2008
    ..South San Francisco, CA) administered every 2 weeks resulted in a longer time to progression but a statistically significant difference in overall survival could not be demonstrated...
  21. pmc Liver resection and ablation for metastatic adrenocortical carcinoma
    R Taylor Ripley
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Ann Surg Oncol 18:1972-9. 2011
    ..Adrenocortical carcinoma (ACC) is a rare disease without effective chemotherapy treated most appropriately with resection. The aim of this study was to evaluate our experience with liver resection for metastatic ACC...
  22. pmc Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma
    Mauricio Burotto
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Oncologist 20:725-6. 2015
    ..The observation of 4 partial responses among the 41 patients indicates that ixabepilone has some activity but not sufficient for further development without greater understanding of mechanisms of sensitivity and resistance...
  23. pmc New syndrome of paraganglioma and somatostatinoma associated with polycythemia
    Karel Pacak
    Section on Medical Neuroendocrinology, Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver NICHD, NIH, Bethesda, MD 20892 1109, USA
    J Clin Oncol 31:1690-8. 2013
    ..The occurrence of ≥ two distinct types of tumors, one of them paraganglioma (PGL), is unusual in an individual patient, except in hereditary cancer syndromes...
  24. ncbi request reprint A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma
    Susan E Bates
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:4724-33. 2004
    ....
  25. pmc Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia
    Zhengping Zhuang
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 367:922-30. 2012
    ..The two mutations were associated with increased HIF-2α activity and increased protein half-life...
  26. ncbi request reprint Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576
    Manish Agrawal
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:650-6. 2003
    ..One can predict that efflux of Pgp substrates also occurs in these tumors. XR9576 provides an efficient way to inhibit this efflux and offers the potential to increase drug exposure in human cancer...
  27. doi request reprint Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
    Wilfred D Stein
    Medical Oncology Branch and Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:907-17. 2011
    ..We utilized a method estimating tumor growth and regression rate constants from serial PSA measurements, and assessed its potential in patients with metastatic castration resistant prostate carcinoma (mCRPC)...
  28. ncbi request reprint Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples
    Lyn Mickley Huff
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Res 65:11694-703. 2005
    ..Demonstration of similar aberrant transcripts in tumor samples obtained from patients with relapsed lymphoma suggests that this phenomenon may also occur clinically...
  29. ncbi request reprint The role of ABC transporters in clinical practice
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 8:411-24. 2003
    ..Further optimism is warranted with the advent of potent, nontoxic inhibitors and new treatment strategies, including the combination of new targeted therapies with therapies aimed at the prevention of drug resistance...
  30. pmc Phase I trial of a new schedule of romidepsin in patients with advanced cancers
    Laleh Amiri-Kordestani
    Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:4499-507. 2013
    ..A secondary objective was to assess the effect of romidepsin on radioactive iodine (RAI) uptake in thyroid cancers...
  31. pmc How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
    Tito Fojo
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Natl Cancer Inst 101:1044-8. 2009
    ..We review recent drug approvals and clinical trials and comment on their relevance to the issue of the spiraling cost of oncology therapeutics. We suggest some standards that would serve as a starting point for addressing these issues...
  32. ncbi request reprint Reversal of multidrug resistance: lessons from clinical oncology
    Susan F Bates
    Molecular Therapeutics Section, Medicine Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Novartis Found Symp 243:83-96; discussion 96-102, 180-5. 2002
    ..Using third generation Pgp antagonists and properly designed clinical trials, it should be possible to determine the contribution of modulators to the reversal of clinical drug resistance...
  33. pmc False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease
    Jay S Fonte
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    Endocr Relat Cancer 19:83-93. 2012
    ..We therefore recommend that patients with false-negative (123)I-MIBG SPECT be tested for SDHB mutations and undergo more regular and close follow-up...
  34. doi request reprint Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience
    Clinton D Kemp
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Ann Thorac Surg 92:1195-200. 2011
    ..This study was undertaken to determine outcomes of patients undergoing pulmonary metastasectomy for ACC...
  35. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889 5015, USA
    J Clin Oncol 23:2726-34. 2005
    ..In a phase II trial, we evaluated the efficacy and safety of ixabepilone in women with metastatic and locally advanced breast cancer...
  36. doi request reprint Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival
    Julia Wilkerson
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer J 15:379-85. 2009
    ..Although PFS should not replace OS in regulatory approval consideration should be given to studies that treat beyond current definitions of progressive disease as a strategy to augment OS...
  37. ncbi request reprint Oligomerization of p53 precedes its association with dynein and nuclear accumulation
    Shana Y Trostel
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cell Cycle 5:2253-9. 2006
    ..They also highlight the importance of an intact microtubule network in the trafficking of crucial cellular proteins...
  38. doi request reprint Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients
    Hui Huang
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 113:2020-8. 2008
    ..A long-term follow-up was conducted of 18 patients with a diagnosis of pheochromocytoma/paraganglioma treated with a combination of cyclophosphamide, vincristine, and dacarbazine (CVD)...
  39. pmc MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors
    Dhaval Patel
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    Surgery 154:1224-8; discussion 1229. 2013
    ..The objective of this study was to determine the feasibility and diagnostic accuracy of measuring serum miRNAs in patients with benign and malignant adrenocortical neoplasms...
  40. ncbi request reprint The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration
    V Koneti Rao
    Center for Cancer Research, National Cancer Institute, NIH, Building 10, Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Mutat Res 583:105-19. 2005
    ..We believe this approach provides a reproducible model in which drugs and eventually, regimens can be compared...
  41. doi request reprint Commentary: Novel therapies for cancer: why dirty might be better
    Tito Fojo
    Medical Oncology Branch, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Oncologist 13:277-83. 2008
  42. pmc Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin
    Robert F Murphy
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health NIH, Bethesda, MD, USA
    Cell Cycle 11:963-73. 2012
    ....
  43. doi request reprint Practical considerations in the evaluation and management of adrenocortical cancer
    Sanjeeve Balasubramaniam
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Oncol 37:619-26. 2010
    ..Finally, physicians caring for these patients need to recognize that Cushing's disease is a debilitating problem that should be managed aggressively; expecting chemotherapy to solve this complication is not appropriate...
  44. ncbi request reprint Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition
    Marianne S Poruchynsky
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cell Cycle 7:940-9. 2008
    ..These data provide a plausible explanation for the neurotoxicity observed clinically and raise the possibility that microtubule stabilization contributes to cytotoxicity...
  45. ncbi request reprint Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
    Richard L Piekarz
    Center for Cancer Research and Cancer Therapeutics Evaluation Program, National Cancer Institute and National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20892 1903, USA
    Clin Cancer Res 12:3762-73. 2006
    ..Electrocardiogram abnormalities, thought to be a class effect, were observed in preclinical animal studies and phase I testing and led to the incorporation of intensive cardiac monitoring in an ongoing efficacy trial...
  46. ncbi request reprint Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs
    Tito Fojo
    Center for Cancer Research, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, United States
    Drug Resist Updat 10:59-67. 2007
    ..Recurrent themes that have emerged will be underscored as we seek to understand how drug resistance occurs...
  47. ncbi request reprint The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies
    Tito Fojo
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Breast Cancer 7:749-56. 2007
    ..This review describes the factors thought to play a role in clinical breast cancer drug resistance and describes potential methods by which it might be circumvented...
  48. pmc Brain metastasis in patients with adrenocortical carcinoma: a clinical series
    Mauricio Burotto
    Center for Cancer Research M B, N T, M V, M E, T F and National Laboratory of Pathology A R, M Q, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 and The George Washington University S M, Rockville, Maryland 20852
    J Clin Endocrinol Metab 100:331-6. 2015
    ..At presentation or at the time of a recurrence, the disease commonly spreads to the liver, lungs, lymph nodes, and bones. The brain has only rarely been reported as a site of metastases...
  49. pmc The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study
    Jan Schovanek
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Building 10, CRC, Room 1E 3140, 10 Center Drive MSC 1109, Bethesda, Maryland 20892 1109, USA
    BMC Cancer 14:523. 2014
    ..This study evaluated the size and age at diagnosis of primary SDHB-related PHEOs/PGLs as independent predictors of their metastatic behavior and outcome (survival)...
  50. doi request reprint Role of radiotherapy in adrenocortical carcinoma
    Jennifer Ho
    Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer J 19:288-94. 2013
    ..Adrenocortical carcinoma (ACC) is a rare and highly malignant tumor usually diagnosed in an advanced stage. Radiation therapy has been a poorly studied and underutilized therapeutic option...
  51. doi request reprint Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development
    Tatiana Vidaurre
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer J 15:366-73. 2009
    ..Studies that use SD as an end point require an adequate control to distinguish antitumor activity from normal variability in time to progression...
  52. doi request reprint Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Maureen Edgerly
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 100:240-2. 2008
    ..We believe that the current version of the CTCAE cannot adequately code the subacute adverse events that commonly occur with today's targeted therapies...
  53. ncbi request reprint Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog
    Manish Agrawal
    Center for Cancer Research, National Cancer Institute Building 10 12C103, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Gynecol Oncol 90:96-9. 2003
    ..This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma of the cervix...
  54. pmc Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data
    Wilfred D Stein
    Medical Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 13:1046-54. 2008
    ..The slow progress in developing new cancer therapies can be attributed in part to the long time spent in clinical development. To hasten development, new paradigms especially applicable to patients with metastatic disease are needed...
  55. ncbi request reprint Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death
    Mikhail V Blagosklonny
    Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 1:113-7. 2002
    ..Following PTX-induced mitotic arrest Jurkat cells undergo apoptosis, whereas MDA-MB-231 cells exit mitosis and form multinucleated cells which then die in a slower non-apoptotic manner...
  56. ncbi request reprint Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations
    Tito Fojo
    Center for Cancer Research, National Cancer Institute NCI, NIH, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Crit Rev Oncol Hematol 53:25-34. 2005
    ....
  57. pmc Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors
    Brigitte C Widemann
    Pediatric and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 27:550-6. 2009
    ....
  58. pmc Radiofrequency ablation for tumor-related massive hematuria
    Ziv Neeman
    Special Procedures Department of Diagnostic Radiology, National Institutes of Health, Clinical Center, Building 10, Room 1C 660, 10 Center Drive, Bethesda, Maryland 20892 1182, USA
    J Vasc Interv Radiol 16:417-21. 2005
    ....
  59. pmc Percutaneous tumor ablation with radiofrequency
    Bradford J Wood
    Diagnostic Radiology Department, Special Procedures Division, National Institutes of Health Clinical Center, Bethesda, Maryland 20892, USA
    Cancer 94:443-51. 2002
    ..To be useful, image-guided, minimally invasive, local treatments will have to meet those expectations without sacrificing efficacy...
  60. ncbi request reprint Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line
    Kevin G Chen
    Division of Oncology, Department of Medicine and Program in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA
    Cancer Res 65:9388-97. 2005
    ....
  61. ncbi request reprint Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells
    Masaki Kitazono
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 12C103, 9000 Rockville Pike, Bethesda, MD 20892 1910, USA
    Blood 99:2248-51. 2002
    ..These studies suggest that FR901228 can increase the efficiency of adenoviral infection in hematopoietic cells...
  62. pmc Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
    Susan E Bates
    Developmental Therapeutics Branch, NCI, NIH, Bethesda, MD, USA
    Br J Haematol 170:96-109. 2015
    ..Together this work supports the safety and activity of romidepsin in T-cell lymphoma, but suggests a complex mechanism of action...
  63. pmc Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients
    Vinay Prasad
    Vinay Prasad and Tito Fojo, National Cancer Institute, National Institutes of Health, Bethesda, MD and Paul R Massey, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
    J Clin Oncol 32:1620-9. 2014
    ....
  64. ncbi request reprint A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist
    Jame Abraham
    Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 94:2333-43. 2002
    ....
  65. ncbi request reprint Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability
    Marianne S Poruchynsky
    Cancer Therapeutics Branch, The NCI Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Biochemistry 43:13944-54. 2004
    ..Unlike reports of mutations resulting in reduced drug affinity, the experimental data and location of mutations are consistent with resistance to HTI-286 mediated by microtubule-stabilizing mutations in beta- or alpha-tubulin...
  66. ncbi request reprint Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity
    Mikhail V Blagosklonny
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cell Cycle 1:67-74. 2002
    ..Transient inhibition of p53- stimulated transcription by numerous stimuli including nucleotide depletion, hypoxia, UV light may be an prevalent mechanism of activation of wt p53 and its downstream pathways...
  67. pmc Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma
    Irina Veytsman
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Rm 12N226, 9000 Rockville Pike, Bethesda, MD, USA
    J Clin Oncol 27:4619-29. 2009
    ..Recommendations are provided to help manage patients with this difficult disease and to improve the quality of their lives...
  68. ncbi request reprint Treatment of metastatic disease in patients with neuroendocrine tumors
    John E Niederhuber
    National Cancer Institute, 31 Center Drive, Room 11A48, Bethesda, MD 20892, USA
    Surg Oncol Clin N Am 15:511-33, viii. 2006
    ..This article addresses the surgical management of endocrine malignancies and the treatment of metastatic disease in patients with neuroendocrine tumors...
  69. doi request reprint Mitosis is not a key target of microtubule agents in patient tumors
    Edina Komlodi-Pasztor
    National Cancer Institute, National Institutes of Health, Building 10, 10 Center Drive, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 8:244-50. 2011
    ..While mitosis-specific inhibitors are effective on only a small fraction of the tumor mass (dividing cells), MTAs target tubulin, a protein that has crucial roles in both mitotic and non-mitotic cells...
  70. pmc MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy
    Erin E Patterson
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 117:1630-9. 2011
    ..The aim of this study was to identify microRNAs (miRNAs or miRs) that are differentially expressed in malignant adrenocortical tumors as compared with benign tumors and assess their potential as diagnostic predictors...
  71. ncbi request reprint Strategies for reversing drug resistance
    Tito Fojo
    Center for Cancer Research, National Cancer Institute, Building 10, Room 12 C 103, 9000 Rockville Pike, Bethesda, MA 20892, USA
    Oncogene 22:7512-23. 2003
    ..Should we succeed, these pioneering basic and clinical studies will have paved the road for future developments...
  72. ncbi request reprint Arsenic trioxide (As(2)O(3)): still a mystery
    Tito Fojo
    Medicine Branch, National Cancer Institute, Bldg 10 Rm 12N226, 9000 Rockville Pike, Bethesda, Maryland 20892 USA
    Cell Cycle 1:183-6. 2002
  73. ncbi request reprint Multidrug resistance in cancer: role of ATP-dependent transporters
    Michael M Gottesman
    Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 2:48-58. 2002
    ..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
  74. pmc Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases
    Bradford J Wood
    Special Procedures, Department of Diagnostic Radiology, Clinical Center, National Institutes of Health Clinical Center, Bethesda, Maryland, USA
    Cancer 97:554-60. 2003
    ....
  75. pmc Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 15:969-75. 2010
    ..Given the toxicity and costs of cancer therapies, perhaps studies should put more weight on long-term survival endpoints than on short-term endpoints that may be less consequential...
  76. pmc Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations
    Kathryn S King
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892 1109, USA
    J Clin Oncol 29:4137-42. 2011
    ..To present data on the high rate of SDHB mutations in patients with metastatic pheochromocytoma/paraganglioma whose initial tumor presentation began in childhood or adolescence...
  77. ncbi request reprint p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53
    Tito Fojo
    Center for Cancer Research, Medicine Branch, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Drug Resist Updat 5:209-16. 2002
    ..Although the importance of p53 in maintaining an established malignant phenotype as well as its role in apoptosis and chemotherapy-induced cytotoxicity are far from settled, a subset of cancers may respond to these strategies...
  78. ncbi request reprint Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway
    Masaki Kitazono
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 99:453-9. 2002
    ....